Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.47 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.47 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7182613 | 0.82 | GABRA1 (0.42) | FFAR1 | |
| SCHEMBL5994572 | 0.78 | PTGER1 (0.47) | FFAR1FFAR4AKR1B1PTGER1PTGER4 | |
| SCHEMBL7189087 | 0.76 | PTGS1 (0.51) | FFAR1FFAR4NR4A2 | |
| SCHEMBL5995941 | 0.75 | PTGER4 (0.44) | FFAR1FFAR4PTGER1PTGER4PTGER3 | |
| SCHEMBL7185160 | 0.75 | FFAR1 (0.50) | FFAR1FFAR4NR4A2 | |
| Oxalic Acid SCHEMBL7593690 | 0.74 | PTPRC (0.70) | FFAR1FFAR4PTGER1PTGER4PTGER3 | |
| SCHEMBL5997202 | 0.74 | PTGER4 (0.43) | FFAR1FFAR4PTGER1PTGER4PTGER3 | |
| SCHEMBL5996822 | 0.74 | PTGER1 (0.43) | FFAR1FFAR4PTGER1PTGER4PTGER3 | |
| SCHEMBL5997090 | 0.74 | PTPRC (0.46) | FFAR1FFAR4PTGER1PTGER4PTGER3 | |
| SCHEMBL7177198 | 0.73 | L3MBTL1 (0.56) | FFAR1FFAR4SMN1; SMN2NR4A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | FFAR1 671/4885FFAR4 1611/4885AKR1B1 700/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | FFAR1 711/4885FFAR4 1526/4885AKR1B1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.